VERRICA PHARMACEUTICALS INC. - COMMON STOCK

Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Commercialize VP-102 For Molluscum and Common Warts in Japan

17 3 2021 06:00:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results

04 3 2021 06:30:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference

03 3 2021 06:30:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference

23 2 2021 06:30:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

17 2 2021 06:30:00 提供 Nasdaq GlobeNewswire

Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference

19 1 2021 06:00:00 提供 Nasdaq GlobeNewswire